The pen is the same. The drug inside it is the same. What changes how it is received, by a coworker, a relative, sometimes an insurer, is the one word attached to why someone takes it.
A qualitative study published in JAMA Network Open on 5 June 2026 interviewed 30 adults across 15 US states about their experience taking GLP-1 receptor agonists such as semaglutide and tirzepatide. It found that the perceived legitimacy of the medication hinges less on the drug itself than on which diagnosis is named alongside it. Diabetes reads as medicine. Weight loss reads, to some of the people around the people taking it, as a shortcut.
What the interviews actually show
The study, led by Isabella de Vere Hunt at Stanford, is not a survey and does not claim to measure how common this feeling is. It is 30 semistructured video interviews, conducted between 22 July and 10 September 2025, with adults recruited through the research-volunteer registry ResearchMatch and snowball sampling, each paid a 75 dollar gift card for their time. Ten participants identified as men, one as nonbinary, nineteen as women; mean age 54.0 years. Twenty-three were taking a GLP-1 drug at the time of the interview, seven had stopped.
One number matters more than the rest for reading the stigma finding correctly: 27 of the 30 participants, 90 percent, had a diagnosis of type 2 diabetes at the time of the interview, even though the study’s own stated aim was to look at experiences “outside its use as treatment for type 2 diabetes.” A published comment on the article, from a group of physicians in Lahore, pointed out exactly that mismatch on 29 June 2026: a sample this heavily diabetic cannot support broad claims about the stigma faced by people using these drugs for weight loss alone, because a diabetes diagnosis already works as what the commenters call a medically legitimized shield. That caution belongs in any use of this study, including this one. What the interviews show is a pattern among a small, self-selected, mostly diabetic group of people willing to talk to researchers about it, not a rate.
The word that changes the reception
Inside that pattern, the pattern itself is consistent and specific. Participants described the same medication read differently depending on the stated reason for taking it. “I think that there is kind of a stigma that it’s a cop-out, that you’re just taking the easy way out rather than doing it with diet and exercise like you should,” one participant said. Another described the results as feeling like “cheating.” A third explained the calculation directly: “I’m careful about who I tell that I’m on it because I do know some people just look at it so negatively… sometimes I say like, ‘I’m on [semaglutide] for diabetes,’ because I feel there is a difference in how it’s viewed for diabetes vs for weight loss.”
Not everyone accepted the premise. One participant rejected it outright: “I don’t really care what people think about how I lost weight. If the subject comes up, I’ll shout it from the rooftops that I found it very effective.” The study does not present the shield strategy as universal, only as one available response to a social hierarchy the participants did not invent.
When the shield is also the gatekeeper
The diabetes framing is not only a social move. For at least one participant, it was the literal condition of coverage: a diagnosis code that improved, in the form of a lower blood sugar reading, cost them access to the drug. The study’s authors put the mechanism plainly in their discussion: eligibility criteria “anchored to diabetes-related thresholds” appeared, in their reading of the interviews, to reinforce the idea that weight loss alone is not a legitimate reason to be on the medication in the first place. Their own recommendation follows from that: “reevaluation of eligibility frameworks may help to mitigate societal stigma surrounding the use of pharmacological therapies for weight management.” That is a call to look at the rule, not at the people the rule sorts.
A bill that would take weight out of the equation
While that eligibility question plays out in clinics and insurance departments, a separate proposal in New York would remove weight itself as a legal basis for worse treatment, in a much wider range of settings than pharmacy benefits. Senate Bill S9803, introduced on 6 April 2026 by Senator Luis Sepúlveda with Liz Krueger and Lea Webb as co-sponsors, would amend New York’s Executive Law to prohibit discrimination based on weight in employment, housing, public accommodations, and education, with an exception, per the bill’s own summary on the New York State Senate’s website, “where deviation may pose a threat to the individual, other patrons, or the general public.” As of today, 28 September 2026, the bill has not moved since it was referred to the Senate Investigations and Government Operations Committee on the day it was introduced, nearly six months ago. It joins similar proposals already tracked elsewhere in this magazine’s coverage of state and city weight-discrimination law; nothing here predicts whether or when it advances.
What this piece is not
This is a report on a qualitative study and a pending bill, not medical or legal advice. Nothing here says whether anyone should take a GLP-1 medication, and nothing here describes dosing, mechanism of action, or expected results; the study itself is about how people talk about a decision they had already made, not about whether to make it. The bill’s status can change at any time; readers who need to act on it should check the Senate’s own bill page, linked below, rather than this article.
Sources: de Vere Hunt et al., “Patient Experiences With GLP-1 Receptor Agonists,” JAMA Network Open 2026;9(6):e2616951, including the published comment of 29 June 2026; New York State Senate, Bill S9803. Read 28 September 2026.